A weekly summary of insider trading highlighting a few notable buying and selling by investors, directors and executives. The ...
Sandra Leung began her legal career prosecuting homicides, a formative experience that she once said taught her "to make ...
William Blair reduced their Q1 2026 EPS estimates for Bristol-Myers Squibb in a research report issued to clients and ...
Bristol Myers Squibb Co. said Cari Gallman, the company’s executive vice president for corporate affairs, will become its ...
Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and growth potential. Learn why BMY stock is a solid ...
This was the stock's third consecutive day of losses.
Bristol Myers Squibb has bolstered its case for Opdivo to be used as a pre-operative treatment for non-small cell lung cancer ...
Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand ...
GlobalData on MSN6d
Bristol Myers Squibb’s Sotyktu shows consistent safety profile in psoriasis trialUS-based pharmaceutical company Bristol Myers Squibb (BMS) has reported results from the POETYK PSO long-term extension (LTE) ...
Squibb announced new five-year results from the POETYK PSO long-term extension trial of Sotyktu treatment in adult patients ...
Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Bristol-Myers Squibb (BMY – Research Report) today. The company’s shares closed yesterday at $54.98. See what stocks ...
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback